Insulin and glyburide therapy: Dosage, severity level of gestational diabetes, and pregnancy outcome

Oded Langer, Yariv Yogev, Elly M Xenakis, Barak Rosenn

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

We sought to investigate the association between glyburide dose, degree of severity in gestational diabetes mellitus (GDM), level of glycemic control, and pregnancy outcome in insulin- and glyburide-treated patients. In a secondary analysis of our previous randomized study, 404 women were analyzed. The association among glyburide dose, severity of GDM, and selected maternal and neonatal factors was evaluated. Severity levels of GDM were stratified by fasting plasma glucose (FPG) from the oral glucose tolerance test (OGTT). Infants with birth weight at or above the 90th percentile were considered large-for-gestational age (LGA). Macrosomia was defined as birth weight ≥4000 g. Well-controlled was defined as mean blood glucose ≤95 mg/dL. The association between glyburide- and insulin-treated patients by severity of GDM and neonatal outcome was evaluated. The dose received for the glyburide-treated patients was 2.5 mg-32%; 5 mg-23%; 10 mg-17%; 15 mg-8%; and 20 mg-20%. Patients were grouped into low (≤10 mg) and high (<10 mg) daily dose of glyburide. A comparison between severity of the disease (fasting plasma glucose categories) and highest dose of glyburide revealed a significant difference between the low-95 FPG and the other severity categories (P =. 02). Of patients in the well-controlled glycemic group, only 6% required the high dose of glyburide (<10 mg). In patients with poor glycemic control (mean blood glucose <95 mg/dL), 38% received the high dose of glyburide (P =. 0001). Comparison between the high glyburide (<10 mg) and the low glyburide dosages (≤10 mg) revealed that the rate of macrosomia was 16% vs 5% and LGA 22% vs 8%, (P =. 01), respectively. No significant difference was found in composite outcome, metabolic complications, and Ponderal Index between the 2 dose groups. Stratification by disease severity revealed a significantly lower rate of LGA for both the glyburide- and insulin-treated subjects. No significant difference was found between metabolic, respiratory, and neonatal intensive care unit (NICU) for patients within each fasting plasma glucose severity category. Glyburide and insulin are equally efficient for treatment of GDM in all levels of disease severity. Achieving the established level of glycemic control, not the mode of pharmacologic therapy, is the key to improving the outcome in GDM.

Original languageEnglish (US)
Pages (from-to)134-139
Number of pages6
JournalAmerican Journal of Obstetrics and Gynecology
Volume192
Issue number1
DOIs
StatePublished - Jan 2005

Fingerprint

Gestational Diabetes
Glyburide
Pregnancy Outcome
Insulin
Therapeutics
Fasting
Gestational Age
Glucose
Birth Weight
Blood Glucose
Neonatal Intensive Care Units
Glucose Tolerance Test

Keywords

  • Gestational diabetes
  • Glyburide
  • Insulin
  • Severity

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

Insulin and glyburide therapy : Dosage, severity level of gestational diabetes, and pregnancy outcome. / Langer, Oded; Yogev, Yariv; Xenakis, Elly M; Rosenn, Barak.

In: American Journal of Obstetrics and Gynecology, Vol. 192, No. 1, 01.2005, p. 134-139.

Research output: Contribution to journalArticle

@article{0064f3c58b954973bed770458c79d79a,
title = "Insulin and glyburide therapy: Dosage, severity level of gestational diabetes, and pregnancy outcome",
abstract = "We sought to investigate the association between glyburide dose, degree of severity in gestational diabetes mellitus (GDM), level of glycemic control, and pregnancy outcome in insulin- and glyburide-treated patients. In a secondary analysis of our previous randomized study, 404 women were analyzed. The association among glyburide dose, severity of GDM, and selected maternal and neonatal factors was evaluated. Severity levels of GDM were stratified by fasting plasma glucose (FPG) from the oral glucose tolerance test (OGTT). Infants with birth weight at or above the 90th percentile were considered large-for-gestational age (LGA). Macrosomia was defined as birth weight ≥4000 g. Well-controlled was defined as mean blood glucose ≤95 mg/dL. The association between glyburide- and insulin-treated patients by severity of GDM and neonatal outcome was evaluated. The dose received for the glyburide-treated patients was 2.5 mg-32{\%}; 5 mg-23{\%}; 10 mg-17{\%}; 15 mg-8{\%}; and 20 mg-20{\%}. Patients were grouped into low (≤10 mg) and high (<10 mg) daily dose of glyburide. A comparison between severity of the disease (fasting plasma glucose categories) and highest dose of glyburide revealed a significant difference between the low-95 FPG and the other severity categories (P =. 02). Of patients in the well-controlled glycemic group, only 6{\%} required the high dose of glyburide (<10 mg). In patients with poor glycemic control (mean blood glucose <95 mg/dL), 38{\%} received the high dose of glyburide (P =. 0001). Comparison between the high glyburide (<10 mg) and the low glyburide dosages (≤10 mg) revealed that the rate of macrosomia was 16{\%} vs 5{\%} and LGA 22{\%} vs 8{\%}, (P =. 01), respectively. No significant difference was found in composite outcome, metabolic complications, and Ponderal Index between the 2 dose groups. Stratification by disease severity revealed a significantly lower rate of LGA for both the glyburide- and insulin-treated subjects. No significant difference was found between metabolic, respiratory, and neonatal intensive care unit (NICU) for patients within each fasting plasma glucose severity category. Glyburide and insulin are equally efficient for treatment of GDM in all levels of disease severity. Achieving the established level of glycemic control, not the mode of pharmacologic therapy, is the key to improving the outcome in GDM.",
keywords = "Gestational diabetes, Glyburide, Insulin, Severity",
author = "Oded Langer and Yariv Yogev and Xenakis, {Elly M} and Barak Rosenn",
year = "2005",
month = "1",
doi = "10.1016/j.ajog.2004.07.011",
language = "English (US)",
volume = "192",
pages = "134--139",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Insulin and glyburide therapy

T2 - Dosage, severity level of gestational diabetes, and pregnancy outcome

AU - Langer, Oded

AU - Yogev, Yariv

AU - Xenakis, Elly M

AU - Rosenn, Barak

PY - 2005/1

Y1 - 2005/1

N2 - We sought to investigate the association between glyburide dose, degree of severity in gestational diabetes mellitus (GDM), level of glycemic control, and pregnancy outcome in insulin- and glyburide-treated patients. In a secondary analysis of our previous randomized study, 404 women were analyzed. The association among glyburide dose, severity of GDM, and selected maternal and neonatal factors was evaluated. Severity levels of GDM were stratified by fasting plasma glucose (FPG) from the oral glucose tolerance test (OGTT). Infants with birth weight at or above the 90th percentile were considered large-for-gestational age (LGA). Macrosomia was defined as birth weight ≥4000 g. Well-controlled was defined as mean blood glucose ≤95 mg/dL. The association between glyburide- and insulin-treated patients by severity of GDM and neonatal outcome was evaluated. The dose received for the glyburide-treated patients was 2.5 mg-32%; 5 mg-23%; 10 mg-17%; 15 mg-8%; and 20 mg-20%. Patients were grouped into low (≤10 mg) and high (<10 mg) daily dose of glyburide. A comparison between severity of the disease (fasting plasma glucose categories) and highest dose of glyburide revealed a significant difference between the low-95 FPG and the other severity categories (P =. 02). Of patients in the well-controlled glycemic group, only 6% required the high dose of glyburide (<10 mg). In patients with poor glycemic control (mean blood glucose <95 mg/dL), 38% received the high dose of glyburide (P =. 0001). Comparison between the high glyburide (<10 mg) and the low glyburide dosages (≤10 mg) revealed that the rate of macrosomia was 16% vs 5% and LGA 22% vs 8%, (P =. 01), respectively. No significant difference was found in composite outcome, metabolic complications, and Ponderal Index between the 2 dose groups. Stratification by disease severity revealed a significantly lower rate of LGA for both the glyburide- and insulin-treated subjects. No significant difference was found between metabolic, respiratory, and neonatal intensive care unit (NICU) for patients within each fasting plasma glucose severity category. Glyburide and insulin are equally efficient for treatment of GDM in all levels of disease severity. Achieving the established level of glycemic control, not the mode of pharmacologic therapy, is the key to improving the outcome in GDM.

AB - We sought to investigate the association between glyburide dose, degree of severity in gestational diabetes mellitus (GDM), level of glycemic control, and pregnancy outcome in insulin- and glyburide-treated patients. In a secondary analysis of our previous randomized study, 404 women were analyzed. The association among glyburide dose, severity of GDM, and selected maternal and neonatal factors was evaluated. Severity levels of GDM were stratified by fasting plasma glucose (FPG) from the oral glucose tolerance test (OGTT). Infants with birth weight at or above the 90th percentile were considered large-for-gestational age (LGA). Macrosomia was defined as birth weight ≥4000 g. Well-controlled was defined as mean blood glucose ≤95 mg/dL. The association between glyburide- and insulin-treated patients by severity of GDM and neonatal outcome was evaluated. The dose received for the glyburide-treated patients was 2.5 mg-32%; 5 mg-23%; 10 mg-17%; 15 mg-8%; and 20 mg-20%. Patients were grouped into low (≤10 mg) and high (<10 mg) daily dose of glyburide. A comparison between severity of the disease (fasting plasma glucose categories) and highest dose of glyburide revealed a significant difference between the low-95 FPG and the other severity categories (P =. 02). Of patients in the well-controlled glycemic group, only 6% required the high dose of glyburide (<10 mg). In patients with poor glycemic control (mean blood glucose <95 mg/dL), 38% received the high dose of glyburide (P =. 0001). Comparison between the high glyburide (<10 mg) and the low glyburide dosages (≤10 mg) revealed that the rate of macrosomia was 16% vs 5% and LGA 22% vs 8%, (P =. 01), respectively. No significant difference was found in composite outcome, metabolic complications, and Ponderal Index between the 2 dose groups. Stratification by disease severity revealed a significantly lower rate of LGA for both the glyburide- and insulin-treated subjects. No significant difference was found between metabolic, respiratory, and neonatal intensive care unit (NICU) for patients within each fasting plasma glucose severity category. Glyburide and insulin are equally efficient for treatment of GDM in all levels of disease severity. Achieving the established level of glycemic control, not the mode of pharmacologic therapy, is the key to improving the outcome in GDM.

KW - Gestational diabetes

KW - Glyburide

KW - Insulin

KW - Severity

UR - http://www.scopus.com/inward/record.url?scp=12844270104&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12844270104&partnerID=8YFLogxK

U2 - 10.1016/j.ajog.2004.07.011

DO - 10.1016/j.ajog.2004.07.011

M3 - Article

C2 - 15672015

AN - SCOPUS:12844270104

VL - 192

SP - 134

EP - 139

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 1

ER -